Objective:To assess the efficacy of ciprofloxacin in treating acute exacerbations of chronic obstructive pulmonary disease (COPD) and to compare the safety of the two drugs in patients with COPD. This was a single-center, randomized, parallel-group, placebo-controlled trial of 250 patients with COPD and a history of COPD who were randomized to receive placebo or ciprofloxacin. Patients with active disease (both COPD and normal-tension patients) received ciprofloxacin alone, or ciprofloxacin plus a methotrexate (MHT) therapy, or both drugs simultaneously. The primary end-point was the percentage of patients who achieved a response to the acute exacerbation of COPD or worsening of COPD after a one-week interval of ciprofloxacin use. Patients treated with ciprofloxacin or methotrexate and who had no response to either drug were compared at weeks 5, 10, and 21, with patients treated with placebo or methotrexate plus a ciprofloxacin therapy, or methotrexate plus a methotrexate therapy. A total of 100 patients were randomised to receive ciprofloxacin and methotrexate (1 or 2) or methotrexate plus ciprofloxacin (1 or 2). The primary efficacy endpoint was the change from baseline of a forced expiratory volume in- exhector (FEV)-fluid clearance time (FECl-FEL) calculated as the ratio of the time to peak FECl-FEL after the first dose of the study drug divided by the baseline value. The secondary end-points were the difference in FECl-FEL after a one-week interval from the start of ciprofloxacin to week 10, and to week 21. Ciprofloxacin was tolerated in most patients in this study (92% vs. 73%), with methotrexate being the most tolerated drug (86% vs. 65%). At week 10, all patients had significantly better improvement in FECl-FEL scores than placebo, ciprofloxacin alone, or methotrexate alone, and methotrexate plus ciprofloxacin was more effective than placebo (FECl-FEL = 90% vs. 87%, p = 0.0004). At week 21, the difference in FECl-FEL in patients with COPD treated with ciprofloxacin plus methotrexate or methotrexate plus ciprofloxacin was not significantly different from placebo (FECl-FEL = 90% vs. 81%, p = 0.2029). The difference in FECl-FEL in patients with COPD treated with ciprofloxacin plus methotrexate was not significantly different from placebo (FECl-FEL = 90% vs. 84%, p = 0.12).
Patients with COPD and a history of COPD who were randomised to methotrexate therapy were compared at baseline and weeks 5, 10, and 21, to those treated with placebo or methotrexate alone, or methotrexate plus ciprofloxacin or methotrexate plus a ciprofloxacin therapy, or both drugs simultaneously (n = 100). Patients were excluded from the study if they were aged >65 years and had not responded to either drug.Patients:The primary end-point was the change from baseline of a forced expiratory volume in- expiratory flow rate (FEV)-fluid clearance time (FECl-FEL) after the first dose of ciprofloxacin (FEV-FEL = 90% vs. 81%, p = 0.0014).
A total of 100 patients were randomised to receive ciprofloxacin alone (n = 100), or ciprofloxacin plus a methotrexate (n = 100), or methotrexate plus ciprofloxacin (n = 100). The primary efficacy endpoint was the change from baseline of a forced expiratory volume in- expiratory flow rate (FEV)-fluid clearance time (FECl-FEL) after the first dose of the study drug (FEV-FEL = 90% vs.
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia), gout, or had received corticosteroid treatment prior to beginning of w/ neutropenia, or were laféers looking to minimize the risk of QT prolongation. If worsening electrocardiogram (�QTMP) or risk of QT prolongationtorsades de pointesemerge, consult a specialist.
Store between 20-25°C.
Do not use in pregnancy, except when clearly determined and with a history of hypersensitivity to ciprofloxacin or other quinolones. Do not take w/ iron or blood. Tablet or capsule form. Not for use in children below 18 years of age. Not suitable for women with pre-existing moderate to severe hepatic impairment. Use with caution in pregnancy. Not recommended for the treatment of CNS disorders. Not recommended for use in children and adolescents with pre-existing moderate to severe hepatic impairment. Before breastfeeding. Not recommended for use during breastfeeding. Contraindicated in pregnancy. Precise dosing and monitoring are recommended for adult patients with pre-existing moderate to severe CNS depression. Monitoring and care are recommended for pediatric patients with pre-existing moderate to severe hepatic impairment. Use w/ other antidepressant/corticosteroid agents. Avoid prolonged use of quinolone antibiotics. Ciprofloxacin should not be used for treatment of otitis media (middle ear infection),annelsart and sinusitis in children. Ciprofloxacin should not be used for treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. If you develop symptoms like chest pain, tight chest, or easy to notice your heart beating faster than you take ciprofloxacin, or you experience QT prolongation with your previous antibiotic treatment, seek immediate medical assistance. Seek support and monitoring right away.
– Use with caution. ciprofloxacin may harm the fetus. The use of ciprofloxacin crosses the placental barrier and may pose risks to mother and child. Due to the potential for harm, monitoring should be sought in the event of ciprofloxacin-associated side effects. – Use only under the guidance of a healthcare professional and following the prescribed recommended dosage. – Avoid alcoholic beverages. – Avoid prolonged use of quinolones. – Ciprofloxacin may have interactions with other medications. – Inform your doctor about any current medications you are taking to avoid adverse effects. – If symptoms persist or worsen, consult a doctor.
Cipro has been associated with a number of side effects including diarrhea, nausea, and headache, although it has also been associated with high blood pressure and heart failure, including a possible association with stroke. It is also known to increase the risk of heart attack and stroke by up to 20 percent. In a small, randomized controlled trial (RCT), ciprofloxacin was found to reduce the risk of serious, non-fatal heart attack and stroke.
Ciprofloxacin is a white blood cell (WBC) drug that has been shown to be highly effective in the treatment of many types of cancers. The drug works by targeting the protein synthesis of white blood cells. The drug is effective in treating multiple types of cancers, including:
In addition to its ability to kill white blood cells, ciprofloxacin is also effective in reducing the incidence of certain types of cancers, such as lung cancer and breast cancer. Ciprofloxacin, when taken as a single dose, is highly effective in the treatment of both lung and breast cancer.
Ciprofloxacin is a potent drug that has been shown to have a wide range of potential side effects. Some of the most commonly reported include:
While ciprofloxacin is a powerful drug, it does have a limited safety profile. It can be associated with an increased risk of a rare but potentially fatal condition called. When taken as a single dose, ciprofloxacin is associated with a small but potentially serious side effect. It is not recommended for children under the age of 6, pregnant or breastfeeding women, or those who have liver disease or should receive a liver transplant.
The safety profile of ciprofloxacin has been studied in more than 100,000 children. It is a potent drug that has been shown to be highly effective in the treatment of certain types of cancers including breast cancer, lung cancer, and ovarian cancer. This is a concern because ciprofloxacin has been found to have a reduced risk of a fatal side effect of the drug. Ciprofloxacin is a well-established drug, and it has not been shown to be a strong or permanent cure for these cancers.
Ciprofloxacin is a drug that has been found to be effective in the treatment of certain types of cancers. It is also associated with a reduced risk of a fatal condition called. This may be a sign that ciprofloxacin is working. The drug is also associated with a low incidence of heart failure, a possible risk factor for the development of this condition. Ciprofloxacin is considered to be a strong drug, and it is often prescribed for patients who are already receiving chemotherapy drugs. In addition, there is a risk of increased heart failure when ciprofloxacin is used in combination with other drugs that treat certain types of cancers.
Treating cancer is important in the management of both the physical and psychological aspects of cancer. It is a common goal in the treatment of cancer.
Cipro (Ciprofloxacin) is used to treat infections caused by bacteria and certain parasites (chlamydia and gonorrhea).
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Ciprofloxacin may be taken with or without food, but it is better to take it at a fixed time. The duration of treatment may vary depending on the infection being treated and the patient's condition. Your doctor will decide the right dosage for you depending on your age, body weight and severity of the infection. Do not take extra medicine without asking your doctor.
Swallow it as whole. Ciprofloxacin may be taken in the dose and duration as advised by your doctor. The dosage may vary depending on the type of infection being treated and the patient's condition.
Before taking Cipro (Ciprofloxacin) tell your doctor or pharmacist if you are allergic to it, if you have any kidney or liver problems, or if you have to take other medicines. Inform your doctor if you have any problems with your stomach or intestine. Do not take Cipro (Ciprofloxacin) if you are pregnant or breastfeeding without consulting your doctor. Do not take Cipro (Ciprofloxacin) during pregnancy or while breastfeeding.
The most common side effects are nausea, diarrhoea, headache and skin rash. Inform your doctor if these side effects last effect or if they bother you. If you experience any severe or persistent side effect, contact your doctor immediately.
Store at a temperature not exceeding 30°C in a dry place.
In case of overdose, get medical help or contact a poison control center immediately.
Side EffectsSome side effects reported with Cipro (Ciprofloxacin) may include:
Tell your doctor if you are taking any prescription or non-prescription medicine, herbal preparation, painkiller, antifungal, opioid or opioid painkiller, anti-inflammatory, anti-depressant, antipsychotic, antidepressant, diuretic or laxative medicine medicine medicine, or painkiller medicine.
Salt Composition in both
Salt Composition
Ciprofloxacin 500mg(same for both)
You Searched
Strip of 10 tablets
We only sell the best substitute from top brands
Our Recommendation
Floxip 500mg Tablet 10s
5,sweetpea.rek.ibufa.ipipipipipipi.com
acas
5, Substitute for Injectable Pills
4,asaki
3,asaki
2,asaki
1,asaki
0,asaki
No, do not use Floxip 500mg Tablet 10s, do not use Floxip 500mg Tablet 10s, do not use Floxip 500mg Tablet 10s, do not use Floxip 500mg Tablet 10s, do not use Floxip 500mg Tablet 10s, no specific instructions about how to use Floxip 500mg Tablet 10s.
Floxip 500mg Tablet 10s is an effective treatment for respiratory infections caused by susceptible microorganisms. It is a combination medication containing both ciprofloxacin 500mg and dexamethasone 500mg, and is not recommended for patients who are sensitive to either substance. Floxip 500mg Tablet 10s can be used in combination with other treatments as prescribed by the doctor, to treat a specific type of bacterial infection (eg, acute tonsillitis). The effectiveness of both ciprofloxacin 500mg and dexamethasone 500mg are similar, as they work in the same way and have similar results.
Stade de France Pharmacy